Advertisement

YM BioSciences Inc.

IBT PR Center > YM BioSciences Inc.

YM BIOSCIENCES INC YMI

$ 0.93

17:40 //

Change: +0.01 +1.09% | Volume: 68,963

YM BioSciences granted Orphan Drug Designation for CYT387

Aug 10, 2010 7:30AM

-JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis-

YM BioSciences Inc. (YMI), Pharmaceutical, Biotechnology, Ontario

YM BioSciences granted Orphan Drug Designation for CYT387

Aug 10, 2010 7:30AM

-JAK1/2 inhibitor currently in Phase II clinical study in myelofibrosis-

YM BioSciences Inc. (YMI), Pharmaceutical, Biotechnology, Ontario

YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study

Aug 05, 2010 7:00AM

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. , announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial...

YM BioSciences Inc. (YMI), Pharmaceutical, Biotechnology, Ontario

YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study

Aug 05, 2010 7:00AM

MISSISSAUGA, ON, Aug. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. , announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial...

YM BioSciences Inc. (YMI), Pharmaceutical, Biotechnology, Ontario

About IBT PR Center

The IBTAnnouncement Service helps investors discover the latest information reported by companies in which they are invested, including changes in voting rights, net asset values, and more.

advertisement

Popular Tags

advertisement